Details for Patent: 10,940,133
✉ Email this page to a colleague
Which drugs does patent 10,940,133 protect, and when does it expire?
Patent 10,940,133 protects SUNOSI and is included in one NDA.
Summary for Patent: 10,940,133
| Title: | Methods of providing solriamfetol therapy to subjects with impaired renal function |
| Abstract: | The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment. |
| Inventor(s): | Zomorodi; Katayoun (San Jose, CA) |
| Assignee: | Jazz Pharmaceuticals Ireland Limited (Dublin, IE) |
| Application Number: | 16/824,560 |
|
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 10,940,133
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Axsome Malta | SUNOSI | solriamfetol hydrochloride | TABLET;ORAL | 211230-001 | Jun 17, 2019 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA (OSA) IN A PATIENT WITH MODERATE RENAL IMPAIRMENT | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
